Hologic Acquisition of Third Wave Gets Antitrust Clearance | GenomeWeb
NEW YORK (GenomeWeb News) – Hologic said today that its proposed $580 million acquisition of Third Wave Technologies has received from the Federal Trade Commission early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
 
Hologic announced two weeks ago that it will acquire Third Wave Technologies for $11.25 per share, a 24 percent premium to Third Wave’s average trading price during the preceding three months. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.